ID   HS-Sch-2
AC   CVCL_8718
SY   HS-sch-2; HSSCH2
DR   CLO; CLO_0050146
DR   BCRJ; 0376
DR   BioSample; SAMN03472028
DR   cancercelllines; CVCL_8718
DR   DepMap; ACH-002066
DR   IARC_TP53; 17934
DR   RCB; RCB2230
DR   Wikidata; Q54896291
RX   PubMed=10891546;
RX   PubMed=28556483;
RX   PubMed=32642732;
RX   PubMed=33707600;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~56 hours (PubMed=10891546).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=10891546; DepMap).
CC   Derived from site: In situ; Peripheral nervous system, left sciatic nerve; UBERON=UBERON_0001322.
ST   Source(s): PubMed=28556483; PubMed=33707600; RCB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 13 (PubMed=33707600)
ST   D18S51: 13,14 (PubMed=28556483)
ST   D19S433: 10.2,14.2 (PubMed=33707600)
ST   D19S433: 14.2 (PubMed=28556483)
ST   D21S11: 29,30
ST   D2S1338: 20
ST   D3S1358: 18
ST   D5S818: 13
ST   D7S820: 8,11 (PubMed=28556483; RCB)
ST   D7S820: 11 (PubMed=33707600)
ST   D8S1179: 14
ST   FGA: 23,26
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 24
//
RX   PubMed=10891546; DOI=10.3892/ijo.17.2.347;
RA   Sonobe H., Takeuchi T., Furihata M., Taguchi T., Kawai A., Ohjimi Y.,
RA   Iwasaki H., Kaneko Y., Ohtsuki Y.;
RT   "A new human malignant peripheral nerve sheath tumour-cell line, HS-Sch-2,
RT   harbouring p53 point mutation.";
RL   Int. J. Oncol. 17:347-352(2000).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:I50-I61(2020).
//
RX   PubMed=33707600; DOI=10.1038/s41598-021-85055-2;
RA   Longo J.F., Brosius S.N., Znoyko I., Alers V.A., Jenkins D.P.,
RA   Wilson R.C., Carroll A.J. III, Wolff D.J., Roth K.A., Carroll S.L.;
RT   "Establishment and genomic characterization of a sporadic malignant
RT   peripheral nerve sheath tumor cell line.";
RL   Sci. Rep. 11:5690-5690(2021).
//